Avalo Therapeutics, Inc.AVTXEarnings & Financial Report
Avalo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted novel therapies for patients living with rare, severe immunological and fibrotic diseases with high unmet medical needs. Its product pipeline includes multiple preclinical and clinical-stage candidates targeting core disease pathways, with primary operations across North America and Europe.
AVTX Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-19.2M
Net Profit
$-30.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.19
Avalo Therapeutics, Inc. Q3 FY2025 Financial Summary
Avalo Therapeutics, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-30.6M (down 232.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-30.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Avalo Therapeutics, Inc. Annual Revenue by Year
Avalo Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $441.0K).
Avalo Therapeutics, Inc. Quarterly Revenue & Net Profit History
Avalo Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-30.6M | N/A |
| Q4 FY2024 | $192.0K | -66.3% | N/A | N/A |
| Q3 FY2024 | $249.0K | +5.5% | $23.0M | 9251.8% |
| Q2 FY2024 | $0 | — | $98.5M | N/A |
| Q1 FY2024 | $0 | — | $-121.3M | N/A |
| Q4 FY2023 | $570.0K | -36.4% | N/A | N/A |
| Q3 FY2023 | $236.0K | -98.4% | $-5.2M | -2215.3% |
| Q2 FY2023 | $643.0K | -37.8% | $-8.2M | -1274.2% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $643000 | $236000 | $570000 | $0 | $0 | $249000 | $192000 | $0 |
| YoY Growth | -37.8% | -98.4% | -36.4% | N/A | N/A | 5.5% | -66.3% | N/A |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $24.2M | $29.3M | $21.0M | $123.7M | $108.3M | $98.5M | $150.7M | $125.1M |
| Liabilities | $31.2M | $14.6M | $13.7M | $224.8M | $110.5M | $75.7M | $17.7M | $33.6M |
| Equity | $-7.0M | $14.7M | $7.3M | $-112.5M | $-13.6M | $21.1M | $133.0M | $91.5M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.0M | $-6.8M | $-30.7M | $-6.2M | $-16.3M | $-11.5M | $-49.1M | $-16.4M |